|
Urologix, Inc. - Comparative Business Analysis Snapshot
Business Description
Urologix, Inc.. The Company's principal activity is to develop, manufacture and market non-surgical, catheter-based therapies for the treatment of benign prostatic hyperplasia. The Group market its control units under the CoolWave(R) and Targis(R) names and its procedure kits under the CTC AdvanceTM, CTCTM, Targis, and ProstaprobeTM names. It uses a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia disease. The Cooled ThermoTherapy can be performed without anesthesia or intravenous sedation and it can be performed in a physician's office or an outpatient clinic. The therapy provides a safe solution that is superior to medication without the complications and side effects inherent in surgical procedures. It manufacture the Targis control unit, CoolWave control unit, and single-use treatment catheters. The Company operates in the United States, Europe, Canada, Asia and other countries.
Competitor Analysis
This analysis compares Urologix, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
